776 related articles for article (PubMed ID: 31594077)
21. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
Yue W; Yuan H; Mao XR; Deng YD; Chen L
Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
[TBL] [Abstract][Full Text] [Related]
22. [A pilot study of peginterferon alfa-2a combined with short-term lamivudine therapy in HBeAg-positive chronic hepatitis B patients].
Huang ZL; Zhao ZX; Deng H; Zhang YF; Lu CR; Gao ZL
Zhonghua Gan Zang Bing Za Zhi; 2010 Jun; 18(6):419-22. PubMed ID: 20587310
[TBL] [Abstract][Full Text] [Related]
23. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
He LT; Ye XG; Zhou XY
World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic efficacy of sequential and simultaneous treatments with interferon-alpha and lamivudine in children with chronic hepatitis B.
Akman SA; Okcu SC; Halicioğlu O; Sutcuoglu S; Anil M; Kizilgunesler A; Bakiler AR
Pediatr Int; 2007 Dec; 49(6):848-52. PubMed ID: 18045284
[TBL] [Abstract][Full Text] [Related]
25. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase.
van Nunen AB; Hansen BE; Suh DJ; Löhr HF; Chemello L; Fontaine H; Heathcote J; Song BC; Janssen HL; de Man RA; Schalm SW
Gut; 2003 Mar; 52(3):420-4. PubMed ID: 12584227
[TBL] [Abstract][Full Text] [Related]
26. [The long-term efficacy of lamivudine in chronic hepatitis B: interim analysis of 3-year's clinical course].
Yao GB; Wang BE; Cui ZY; Yao JL; Zeng MD
Zhonghua Nei Ke Za Zhi; 2003 Jun; 42(6):382-7. PubMed ID: 12895320
[TBL] [Abstract][Full Text] [Related]
27. Combination therapy for children with chronic hepatitis B virus infection.
Dikici B; Bosnak M; Bosnak V; Dagli A; Ece A; Yagci RV; Haspolat K
J Gastroenterol Hepatol; 2002 Oct; 17(10):1087-91. PubMed ID: 12201869
[TBL] [Abstract][Full Text] [Related]
28. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study.
Serfaty L; Thabut D; Zoulim F; Andreani T; Chazouillères O; Carbonell N; Loria A; Poupon R
Hepatology; 2001 Sep; 34(3):573-7. PubMed ID: 11526544
[TBL] [Abstract][Full Text] [Related]
29. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
Cao ZH; Ma LN; Zhang HW; Liu YL; Chen XY
J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
[TBL] [Abstract][Full Text] [Related]
30. An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B.
Yao G; Cui Z; Wang B; Yao J; Zeng M
Chin Med J (Engl); 2002 Dec; 115(12):1814-8. PubMed ID: 12622930
[TBL] [Abstract][Full Text] [Related]
31. [Prolonged duration of the routine pegylated-interferon alfa-2a therapy produces superior virological response in HBeAg-positive chronic hepatitis B patients: a single-center cohort study].
Zhu YY; Wu YL; Chen J; Zheng Q; Dong J; Jiang JJ
Zhonghua Gan Zang Bing Za Zhi; 2012 Oct; 20(10):737-41. PubMed ID: 23207332
[TBL] [Abstract][Full Text] [Related]
32. [Efficacy of 104-week sequential therapy with telbivudine or entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24-week therapy with pegylated interferon-α-2a].
Luo XD; Chen XP; Chen R; Chen XF; Huang J
Zhonghua Gan Zang Bing Za Zhi; 2016 Apr; 24(4):241-5. PubMed ID: 27470620
[TBL] [Abstract][Full Text] [Related]
33. Combination of Entecavir/Peginterferon Alfa-2a in Children With Hepatitis B e Antigen-Positive Immune Tolerant Chronic Hepatitis B Virus Infection.
Rosenthal P; Ling SC; Belle SH; Murray KF; Rodriguez-Baez N; Schwarzenberg SJ; Teckman J; Lin HS; Schwarz KB;
Hepatology; 2019 Jun; 69(6):2326-2337. PubMed ID: 30318613
[TBL] [Abstract][Full Text] [Related]
34. Lamivudine therapy for children with chronic hepatitis B.
Liberek A; Szaflarska-Popławska A; Korzon M; Łuczak G; Góra-Gebka M; Łoś-Rycharska E; Bako W; Czerwionka-Szaflarska M
World J Gastroenterol; 2006 Apr; 12(15):2412-6. PubMed ID: 16688835
[TBL] [Abstract][Full Text] [Related]
35. Treatment of chronic hepatitis B: case selection and duration of therapy.
Leung N
J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
[TBL] [Abstract][Full Text] [Related]
36. [Preliminary results of interferon alpha-2a and lamivudine combination therapy regimen in children with chronic hepatitis B].
Aşik Akman S; Cokçeken Okçu S; Anil OH; Köse S; Bakiler AR
Mikrobiyol Bul; 2006; 40(1-2):47-53. PubMed ID: 16775956
[TBL] [Abstract][Full Text] [Related]
37. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
[TBL] [Abstract][Full Text] [Related]
38. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.
Perrillo RP; Lai CL; Liaw YF; Dienstag JL; Schiff ER; Schalm SW; Heathcote EJ; Brown NA; Atkins M; Woessner M; Gardner SD
Hepatology; 2002 Jul; 36(1):186-94. PubMed ID: 12085364
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
[TBL] [Abstract][Full Text] [Related]
40. [Clinical characteristics of hepatic flare and efficacy of antiviral therapy in pregnant women with chronic hepatitis B virus infection].
Ding Y; Sheng QJ; Zhang C; Wu YY; Yuan SY; Xia TT; An ZY; Dou XG
Zhonghua Gan Zang Bing Za Zhi; 2019 Feb; 27(2):106-111. PubMed ID: 30818914
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
